Numira Biosciences, Inc. Names Anthony Purchio, Ph.D., Chief Scientific Officer

IRVINE, Calif., May 15 /PRNewswire/ -- Numira Biosciences announced today that Anthony F. Purchio, Ph.D. has joined the Company as Chief Scientific Officer. He will guide Numira's research and development efforts, as well as provide assistance in the company's business development activities.

Dr. Purchio comes to Numira with extensive product development experience in the areas of molecular imaging, genetics, and in-vivo reporter systems for use in a wide-range of pathologies. Prior to joining Numira, he served as Vice President and Chief Scientific Officer at Xenogen Corporation, where he was responsible for developing animal models for in-vivo drug assessment in the areas of infectious diseases, oncology, neurology, metabolism and toxicology. Prior to that, Dr. Purchio held senior research and development positions at Hepatix, Inc., Advanced Tissue Sciences, Bristol-Myers Squibb Pharmaceutical Research Institute, and Molecular Genetics, Incorporated.

Numira President & CEO, Michael Beeuwsaert said, "Dr. Purchio is the right person at the right time to help transition our company to the next level in terms of advancing our technology pipeline and preparing multiple products for market launch. We are highly confident that his unique blend of industry experience and technological acumen will enable us to rapidly expand our product catalog."

Dr. Purchio commented, "I am excited to be joining such an experienced and dedicated team of industry professionals. Numira is uniquely positioned to capitalize on the technology convergence of software, biomedical imaging systems and our ever increasing understanding of genomics. Numira's innovative products and services combined with their strategic focus on the drug discovery arena are a winning combination. I look forward to leveraging my past experiences to help Numira deliver leading-edge solutions to this important market segment."

Dr. Purchio has authored 130 peer-reviewed articles and is named on 17 issued patents. He holds a doctorate in Experimental Pathology from University of Colorado Health Sciences Center and completed post-doctoral training at the Molecular Biology Institute, UCLA.

About Numira Biosciences

Numira Biosciences is a specialty R&D tools company focused on leveraging advances in genetics and molecular imaging to create a catalog of novel, high- value products that provide researchers with unprecedented insight into genomics, developmental biology, mechanisms of disease, drug efficacy, and toxicity.

For more information, please visit the company's website at www.numirabio.com.

CONTACT: Michael Beeuwsaert, President & CEO of Numira Biosciences Inc.,+1-949-623-8603, mbeeuwsaert@numirabio.com

Web site: http://www.numirabio.com/